Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04496687

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

The International Spontaneous Coronary Artery Dissection "iSCAD" Registry (SCAD)

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
SCAD Alliance · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its recurrence. This observational study will be prospective and retrospective in its recruitment and will collect clinical information to better understand the natural history and prognosis for SCAD.

Detailed description

Spontaneous Coronary Artery Dissection (SCAD) is an under-diagnosed cause of acute coronary syndrome (ACS), myocardial infarction (MI) and sudden cardiac arrest. The inner lining of the coronary artery splits and allows blood to seep into the adjacent layer, forming a blockage (hematoma), or the artery continues to tear, creating a flap of tissue that blocks blood flow in the artery. SCAD strikes generally healthy, younger individuals (average age 42) who do not have traditional cardiac risk factors. Warning signs of SCAD encompass the full range of ACS and MI symptoms, from vague to classic. The cause of SCAD is currently unknown and the psychosocial impact of SCAD is traumatizing. The work of the iSCAD Registry will encompass the physical and psychosocial study of SCAD.

Conditions

Timeline

Start date
2019-03-08
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2020-08-03
Last updated
2024-12-17

Locations

31 sites across 2 countries: United States, Australia

Source: ClinicalTrials.gov record NCT04496687. Inclusion in this directory is not an endorsement.